Refractory Head and Neck Squamous Cell Carcinoma
3 clinical trials · Condition
◉ Watch Refractory Head and Neck Squamous Cell Carcinoma
| Record | Firm | Date |
|---|---|---|
| Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment (NCT06589804) | National Cancer Institute (NCI) | 2025-03-27 |
| Losartan, Pembrolizumab and Stereotactic Body Radiation Therapy for the Treatment of Patients With Locally Recurrent, Refractory or Oligometastatic Head and Neck Squamous Cell Carcinoma (NCT06211335) | University of California, Davis | 2023-12-07 |
| IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors (NCT05039801) | M.D. Anderson Cancer Center | 2021-09-30 |
Track Refractory Head and Neck Squamous Cell Carcinoma automatically
Every clearance here is in the API, with alerts when new ones post.